Consensus Codexis, Inc.

Stocks

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-15 EDT			5-day change	1st Jan Change
1.360 ^USD	+5.43%		0.00%	-16.56%

09-28	Codexis, Inc. Enters Into An Agreement With Pioneering siRNA Drug Innovator To Leverage The ECO Synthesis Manufacturing Platform To Create Stereo-Defined siRNA	CI
08-11	Codexis, Inc., Q2 2026 Earnings Call, Aug 11, 2026

Evolution of the Average Target: Codexis, Inc.

Evolution of the Target Price: Codexis, Inc.

Changes in Analyst Recommendations: Codexis, Inc.

f031ec11dc3d3125caab6.lIk9jF1orMaj7FN7LF37ny_KkkpeNy6CFhZtRLTlAvE.7MJ_yRYl1JmThQQ6Smyo_mb6x3IyTUSxUHorDOayTsP92Q_nCCqagNmCaw~0866fb2a73eea4aca8200ee0c63e820d

Analysts' recommendations: Codexis, Inc.

24-08-19	Benchmark Capital Downgrades Codexis to Hold From Buy	MT
24-05-30	Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target	MT
24-02-29	Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9	MT
23-11-07	Benchmark Downgrades Codexis to Hold From Buy	MT
23-11-06	Piper Sandler Trims Price Target on Codexis to $10 From $14, Maintains Overweight Rating	MT
23-08-14	Stifel Adjusts Price Target on Codexis to $5 From $9, Maintains Buy Rating	MT
23-05-09	Benchmark Adjusts Price Target on Codexis to $9 From $15, Keeps Buy Rating	MT
23-05-09	HC Wainwright Downgrades Codexis to Neutral From Buy	MT
23-02-27	HC Wainwright Adjusts Price Target on Codexis to $9 From $15, Keeps Buy Rating	MT
23-01-19	Piper Sandler Adjusts Price Target on Codexis to $23 From $22, Maintains Overweight Rating	MT
22-11-07	HC Wainwright Adjusts Price Target on Codexis to $15 From $25, Maintains Buy Rating	MT
22-08-08	HC Wainwright Adjusts Codexis' Price Target to $25 From $27, Reiterates Buy Rating	MT
22-07-18	HC Wainwright Adjusts Codexis' Price Target to $27 from $38, Keeps Buy Rating	MT
22-07-15	Cowen & Co Adjusts Codexis Price Target to $21 From $39, Maintains Outperform Rating	MT
22-07-15	Piper Sandler Adjusts Codexis' Price Target to $22 From $35, Reiterates Overweight Rating	MT
21-11-05	HC Wainwright Adjusts Price Target on Codexis to $38 From $33, Maintains Buy Rating	MT
21-10-15	Codexis : HC Wainwright Adjusts Codexis' Price Target to $33 from $28, Keeps Buy Rating	MT
21-08-06	Codexis : Piper Sandler Adjusts Codexis' Price Target to $34 From $32, Maintains Overweight Rating	MT
21-06-18	Codexis : HC Wainwright Adjusts Codexis' Price Target to $27 From $26, Keeps Buy Rating	MT
21-04-12	Codexis : Piper Sandler Starts Codexis at Overweight With $32 Price Target	MT
21-03-01	Codexis : Stifel Starts Codexis at Buy with $30 Price Target	MT
21-02-26	Codexis : HC Wainwright Adjusts Codexis' Price Target to $26 From $21, Maintains Buy Rating	MT
20-12-30	Codexis : Benchmark Capital Adjusts Codexis PT to $29 From $21, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CODEXIS, INC.					+376.19%
	WUXI APPTEC CO., LTD.					+24.45%
	ARGENX SE					+37.29%
	LONZA GROUP AG					+17.78%
	IQVIA HOLDINGS INC.					+13.35%
	REVOLUTION MEDICINES, INC.					+33.93%
	BEONE MEDICINES AG					+23.91%
	CELLTRION, INC.					+48.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+20.17%
	BIONTECH SE					+31.29%
	Average					+62.73%
	Weighted average by Cap.					+27.33%